The Albanese Government confirmed its decision to defer the bigger decisions, or any decisions, on the Health Technology Assessment Review and signalled a push to lock in new cost‑recovery and agreement arrangements within the next 12 months. A vaguely worded commitment on biosimilars. …
Budget confirms what we already knew and what we had guessed. What a surprise
May 12, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 - - Australian Biotech -
OncoSil Medical establishes scalable Australian production after successful manufacturing validation
July 13, 2026 - - Australian Biotech -
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 - - Australian Biotech -
Patrys and Yale agree revenue share to advance deoxymab platform
July 13, 2026 - - Australian Biotech -
Mesoblast reports strong cell therapy revenue as first year as uptake grows
July 13, 2026 - - Latest News -
What is it with this organisation's obsession with pharmacy and Europe?
July 13, 2026 - - Latest News -
The inevitability of disappointment over a reform process that has devolved into word games
July 12, 2026 - - Latest News